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ABSTRACT
Objective: Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not 
detected early and treated appropriately. A large number of antihypertensive drugs alone or in various combinations are available, and physicians 
need to choose most appropriate drug for a particular patient. Pharmacoeconomic and drug utilization studies at regular intervals help physicians to 
prescribed rational drugs with high efficacy along with minimal cost.
Methods: The prospective observational study was conducted at Seth H. J. Mahagujarat Hospital from July to December 2013. 250 hypertensive 
patients, attending medicine outpatient department were included for drug utilization study and 100 hypertensive patients, attending in patients 
department were included for pharmacoeconomics analysis during the study period.
Result: The most frequently prescribed antihypertensive drug as monotherapy, as combination therapy and in fixed dose combinations was calcium 
channel blocker (Amlodipine). Generic drugs showed same efficacy as brand drug, but both drugs were significantly differed in the prize. Among 100 
inpatients admitted for the hypertensive condition in general ward total of direct medical cost was 65.19% and total of indirect medical cost was 
34.81%. β-blocker and diuretics were the most effective therapy which is followed by the clonidine, envas (Enalapril), and then, amlodipine.
Conclusion: We concluded from this study that use of β-blockers and diuretics were most cost-effective for the hypertensive patients in this study.
Keywords: Antihypertensive drugs, Drug utilization study, Pharmacoeconomics analysis.
INTRODUCTION
Hypertension (HTN) is considered as silent killer. It is one of the most 
significant risk factors for cardiovascular (CV) morbidity and mortality 
resulting from target organ damage to blood vessels of the heart, brain, 
kidney, and eyes [1]. Worldwide, raised blood pressure is estimated to 
cause 7.5 million deaths, about 12.8% of the total of all deaths. This 
accounts for 57 million disability adjusted life years (DALYS) or 3.7% of 
total DALYS [2]. Globally CV disease accounts for approximately 17 million 
deaths a year, nearly one-third of the total [3], of these complications of 
HTN account for 9.4 million deaths worldwide every year [4]. Premature 
death, disability, personal and family disruption, loss of income, and 
health-care expenditure due to HTN, take a toll on families, communities, 
and national finances. In low- and middle-income countries many people 
do not seek treatment for HTN because it is prohibitively expensive [5]. 
Over the period 2011-2025, the cumulative lost output in low- and 
middle-income countries associated with noncommunicable diseases is 
projected to be US$ 7.28 trillion [6]. The annual loss of approximately 
US$ 500 billion due to major noncommunicable diseases amounts 
to approximately 4% of gross domestic product for low- and middle-
income countries. CV disease including HTN accounts for nearly half of 
the cost [7]. Blood pressure drugs work in several ways, such as removing 
excess salt and fluid from the body, slowing the heartbeat or relaxing 
and widening the blood vessels. A wide range of antihypertensive drugs 
belonging to different pharmacological classes is available. Choice of 
drugs for a particular patient changes because of factors such as efficacy, 
side effects, cost, and development of newer drugs. Hence, it is necessary 
to survey prescription patterns as a component of medical audit for 
monitoring, evaluation, and necessary modifications in prescribing 
practices to achieve rational and cost-effective medical care.
The World Health Organization addressed drug utilization as the 
marketing, distribution, prescription and use of drugs in society, 
considering its consequences, either medical, social, and economic. 
The main goal of drug utilization research is to assist the rationale use 
of drugs in populations. With the knowledge on how drugs are being 
prescribed and used, a discussion on rational drugs use and suggestions 
on measures to improve prescribing habits should be more efficiently. 
Descriptive studies are part of drug utilization research and their 
main target is to describe variations and trends in the extend, costs, 
and quality of drug use among individuals and populations [8]. Drug 
utilization research not only can profile the discrepancy that exists 
between true need and therapeutic practice but also a tool to correct 
it. If it is unquestionable the importance of promoting compliance on 
prescribed medicines, it is not of less importance, to avoid overuse of 
drugs, which may be responsible for an increase in adverse events, 
iatrogenic diseases, and unnecessary costs. Since drug utilization 
studies are designed only to provide the existing distribution of 
variables, without any regard for causality, external validity of such 
studies is limited [9].
Joint National Committee guidelines recommend diuretics as the first 
choice in hypertensive patients with no comorbidities [10]. However, 
differences still exist between these guidelines and the initial drug of 
choice in clinical practice [11]. It is estimated that nearly $60 billion is 
spent on managing HTN and its complications annually in the United 
States, yet only 34% of the patients treated with antihypertensive 
medications reach desired blood pressure goals [10,12]. Recent studies 
have stated that much of this increase in cost is attributable to the 
introduction of new and generally more costly brand name drugs that 
replace older and less expensive medications [13].
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Pharmacoeconomics consists of analysis and evaluation of outcomes 
(clinical, economic, or humanistic), cost consequences, and cost 
comparison. Pharmacoeconomic evaluations can be applied to assess the 
value of treatments, to compare the medical cost and health outcomes 
associated with new therapies/medicines to the cost and to determine 
the outcome of the existing alternative treatment. Currently European 
countries are making the maximum use of pharmacoeconomic data for 
reimbursement and other financial decisions, and most have officially 
introduced pharmacoeconomics guidelines in their countries. Australia 
in comparison with European countries has a relatively well-developed 
pharmacoeconomic structure. Countries in the North American 
continent, South American continent, and South Africa have introduced 
the concept of pharmacoeconomics and outcomes research data 
lately. Countries in Asia such as China, Hong Kong, Japan, Korea, and 
Singapore have a well-developed pharmacoeconomics and outcomes 
research structure [14]. In India, full proof system yet to be developed, 
where the majority of patients are below the poverty line and high 
cost of treatment is main reason for nonadherence to the treatment. 
This study was designed to analyze the drug utilization patterns and 
pharmacoeconomic analysis of antihypertensive drugs prescribed to 
hypertensive patients.
METHODS
The prospective observational study was conducted at Seth H J 
Mahagujarat Hospital during the period of July 2013 to December 2013. 
Ethical approval was obtained from the Institutional Ethics Committee 
of Rathi Hospital, Ahmedabad. Beer’s criteria were used to analyze 
proportion distribution compare with standard guideline.
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250 hypertensive patients, attending medicine outpatient department 
were included for drug utilization study and 100 hypertensive patients, 
attending in patients department were included for pharmacoeconomics 
analysis during the study period (Fig. 1).
Data analysis
The proportion of patients using different classes of antihypertensive 
was calculated and analyzed using the M.S. Excel. Mean±standard error 
of mean is utilized for statistical analysis. All the costs including direct 
costs and indirect costs were collected in the per forma, which includes: 
Cost of medication, cost of medical consultation, cost of laboratory tests, 
cost of transport and meal, indirect cost due to loss of productivity. The 
economic outcome, cost minimization analysis, cost of illness, and cost-
effectiveness analysis measured as QALY - quality adjusted life years.
RESULT AND DISCUSSION
In this study, 136 patients (54.4%) were males and 114 (45.6%) were 
females indicating 8.8% higher prevalence of HTN in male population. 
As shown in Table 1, the prevalence of HTN increases with age. Hence, 
age is one of the main factors for HTN. Our study showed that out of 
250, 51 patients have hereditary condition of HTN. Hence, family 
history of elevated blood pressure is one of the strongest risk factors 
for future development of HTN in individuals. Among 250 patients, 
112 patients have comorbid condition along with HTN. In our study, 
finding the majority of the patients 66 (57.89%) have diabetes 
mellitus (DM) followed by myocardial ischemia 26 (22.80%), thyroid 
complications 16 (14.03 %), asthma 04 (3.50%), chronic obstructive 
pulmonary disease (COPD 1) (0.87%), and migraine 1 (0.87). The most 
frequently prescribed antihypertensive drug group was angiotensin 2 
receptor blockers for patients who have comorbidity of DM (51.5%). 
Distribution of hypertensive patient according to age, duration of HTN, 
body mass index (BMI), systolic blood pressure, and diastolic blood 
pressure were showed in Table 1. The age difference between two 
gender groups (p≤0.05) was statistically significant.
In the Table 2, showed that BMI of patients fall in normal range 
(49.6%). Although obese patient was more found in case of female 
compared to male patients and the mean BMI of the patients in our 
study were approximately 23.95 kg/m2 which imply that the patients 
are normal range. While in one of the clinical work showed average 
BMI 27.16±2.85 in male patients and 26.40±3.65 in female patients 
during course of antidiabetic therapy, which implies that the patients 
were overweight (BMI ≥25 kg/m2) and were on the borderline of 
becoming obese (BMI ≥30 kg/m2), which in itself is a well-recognized 
significant risk factor for DM [15] and HTN. In most of the studies, 
being overweight was associated with a 2-fold to 6-fold increase in 
the risk of developing HTN. Framingham study suggests that 10% 
increase in weight a rise of 6.5 mm Hg in systolic pressure [16]. It also 
suggested that 65% of the risk for HTN in women and 78% in men 
can be related to obesity. The study done in Jaipur urban (both sexes) 
and rural studies (only males) [17], the Haryana rural study [18], 
the Chennai urban population study [19] as well as the Bombay 
executive study [20] have all shown a higher weight and BMI among 
hypertensive groups.
Distribution of drug in hypertensive patient – Monotherapy
A total of 187 (74.8%) patients received monotherapy. This study 
revealed that calcium channel blockers were the drugs of choice for 
hypertensive patients because it is prescribed to 54 (28.87%) patient 








Age (years) Male 136 61.448±0.889 0.499
Female 114 56.543±0.880
Total 250 59.212±0.684
DHTN (months) Male 136 49.65±4.8506 1.601
Female 114 42.798±4.937
Total 250 46.528±3.4685
BMI (kg/m2) Male 136 23.305±0.436 1.764
Female 114 24.735±0.5535
Total 250 23.95±0.3487
SBP (mm of Hg) Male 136 143.23±1.616 0.499
Female 114 149.34±1.969
Total 250 146.02±1.269
DBP (mm of Hg) Male 136 84.338±0.743 0.024
Female 114 85.394±0.758
Total 250 84.82±0.5319
HTN: Hypertension, SBP: Systolic blood pressure, BMI: Body mass index, 
DBP: Diastolic blood pressure
Table 2: Classification of BMI in hypertensive patients
Classification BMI (kg/m2) Male (%) Female (%) Total (%)
Underweight <18.50 22 (16.17) 07 (06.14) 29 (11.60)
Normal range 18.50-24.99 67 (49.26) 57 (50.00) 124 (49.60)
Overweight 25.00-29.99 35 (25.73) 33 (28.94) 68 (27.2)
Obese ≥30.00 12 (08.82) 17 (14.91) 29 (11.6)
Total 136 (100.0) 114 (100.0) 250 (100.0)
BMI: Body mass index
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of HTN as a single drug therapy, followed by the fixed dose combination 
(FDC) of β-blockers with amlodipine 42 (22.45%), β-blockers 
37 (19.78), angiotensin 2 receptor blocker 23 (12.29%), diuretics 
9 (4.81%), angiotensin converting enzyme inhibitors 9 (4.81%), 
centrally acting drug 2 (1.06%), and others. Diuretics are generally 
recommended as first-line therapy for treatment of HTN (JNC V; JNC VI) 
(Fig. 2). Utilization of diuretics in this study was 7.44% as monotherapy. 
Lesser use of diuretics in this study may be due to adverse effect of 
diuretics on glucose homeostasis and lipid profile [21]. In an Indian 
study, 40% of patients received monotherapy [22]. Tiwari et al. study 
also support this result of high use of calcium channel blockers as 
monotherapy (Fig. 2).
Distribution of drugs in hypertensive patients
A total of 49 (19.6%) patients received dual therapy. Among them, 
15 patients received Ca2+ channel blocker along with other drugs 
such as atenolol, revolol, enalapril, telmisartan, and clonidine, 
(telmisartan +atenolol) (losartan + hydrochlorthiazide). Other 
14 patients received combination of FDCs (Ca++ channel blocker 
+ β-blocker) along with other drugs such as enalapril, clonidine, 
losartan, telmisartan, while 9 patients received combination of 
diuretics (furosemide) along with other drugs such as amlodipine, 
atenolol, and telmisartan. The remaining 11 patients prescribed 
β-blocker along with telmisartan, losartan, enalapril, clonidine, and 
amlodipine (Table 3). Only one patient prescribed the quadruple 
therapy with combination of amlodipine, hydrochlorothiazide, 
clonidine, and metoprolol.
Associated comorbidity with HTN
In our study, finding the majority of the patients 66 (57.89%) have 
DM followed by myocardial ischemia 26 (22.80%), thyroid disease 
16 (14.03%), asthma 04 (3.50%), COPD 1 (0.87%), and migraine 1 (0.87). 
A study carried out by Olusegun Adesola found 43 hypertensive patients 
(n=240) had coexisting DM [23]. In one clinical study, found that the 
most common comorbidity in HTN was DM, 98 (38.4%); followed by 
dyslipidemia in 50 (19.6%), bronchial asthma in 28 (11.0%), and renal 
diseases in 12 (4.7%) [24]. Another study showed that the highest 
comorbid condition found with HTN were diabetes (13%), followed by 
hyperlipidemia (7.5%), renal disease, and obesity (6.5% each). Peptic ulcer 
disease and stroke (4% each) and congestive cardiac failure (3.5%) [25].
Pharmacoeconomic study
Cost minimization
There is no significant difference between efficacies of these two drugs 
(branded vs. generic drugs) (p>0.05), these drugs do significantly differ 
in the prizes. Hence, prescribing generic as their cost is low compared 
to branded products which is a good option for trust based hospital and 
also beneficial for rural people (Table 4).
Cost of illness
Total of direct medical costs among 100 inpatients admitted due to 
hypertensive crises in general ward was 65.19%, among them, cost of 
health personnel (physician and nursing charges) constituted 25.43%, 
cost of medication constituted 28.53%, and laboratory cost constituted 
11.24% of from the direct medical costs for the hypertensive condition.
Fig. 1: Overview of methodology (CRF – Case record form, BMI – Body mass index, BP – Blood pressure)
Fig. 2: Drug utilization of antihypertensive drug as a monotherapy
123
 Solanki and Patel 
Asian J Pharm Clin Res, Vol 10, Issue 3, 2017, 120-124
Total of indirect medical costs among 100 inpatients admitted for the 
hypertensive condition in general ward is 34.81%, among them, cost 
of loss of productivity (missed earning days) constituted 15.29, cost of 
transportation, and meal are 19.51% from the indirect medical costs for 
hypertensive condition.
Cost-effectiveness analysis
Diuretics and β-blockers were the most effective therapy which is 
followed by the clonidine, enalapril, amlodipine, and other class 
of drugs. The cost-effectiveness studies alter with comorbidities 
associated with HTN. In this study, the majority of patients associated 
with CV disorders so β-blocker is most cost-effective drug in this study.
Cost effectiveness is dependent on QALYs. Higher the QALYs better the 
cost effectiveness which directly affects the total cost and ultimately 
benefited to patients and overall economic burden of therapy is reduced 
(Table 5).
CONCLUSION
The most frequently prescribed antihypertensive drug group was 
calcium channel blocker as monotherapy, though diuretics are the first 
line choice of drug therapy for the HTN. Lesser use of diuretics in this 
study may be due to adverse effect of diuretics on glucose homeostasis 
and lipid profile. The most prevalent combination of drugs prescribed 
were calcium channel blockers + β-blockers as dual, triple, and as FDCs.
In pharmacoeconomics study, we concluded that it is beneficial for 
developing countries where the majority of people below the poverty 
line and nonadherence to therapy are observed only because of the 
high cost of the treatment. By the cost minimization, we concluded that 
use of generic drug significantly affects the cost of medication without 
change in the safety and efficacy. In cost of illness, we concluded that 
indirect cost was invisible to the patient but it covers near to 30% of 
the total cost, by proper knowledge of pharmacoeconomics we can 
minimize the indirect cost of treatment by minimizing the duration of 
stay depending on disease condition. Finally, we concluded from this 
study that use of β-blockers and diuretics were most cost-effective for 
the hypertensive patients in this study.
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